Mizuki Onozawa

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Ejection Fraction

Prostate Cancer

Prognostic Factors

Top Venues

Japanese journal of clinical oncology

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Satoru Taguchi, Mizuki Onozawa, Shiro Hinotsu, Taketo Kawai, Takeshi Mitomi, Satoshi Uno, Haruki Kume
A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy. Japanese journal of clinical oncology (2023)
Kozaburo Tanuma, Koji Kawai, Satoshi Nitta, Masanobu Shiga, Takashi Kawahara, Hiromitsu Negoro, Mizuki Onozawa, Takamitsu Inoue, Hiroyuki Nishiyama, Jun Miyazaki
Improved survival of poor-risk non-seminomatous germ cell tumor patients: real-world data from a single institute in Japan. Japanese journal of clinical oncology (2022)
Jasmine Lim, Mizuki Onozawa, Marniza Saad, Teng-Aik Ong, null null, null null, null null, Rohan Malek, Hideyuki Akaza
Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high- and middle-income Asian countries. Cancer science 112 (6) (2021)
Jasmine Lim, Shiro Hinotsu, Mizuki Onozawa, Rohan Malek, Murali Sundram, Guan C Teh, Teng-Aik Ong, Shankaran Thevarajah, Rohana Zainal, Say C Khoo, Shamsuddin Omar, Noor A Nasuha, Hideyuki Akaza
Modified J-CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy. Cancer medicine 9 (24) (2020)
Mizuki Onozawa, Hideyuki Akaza, Shiro Hinotsu, Mototsugu Oya, Osamu Ogawa, Tadaichi Kitamura, Kazuhiro Suzuki, Seiji Naito, Mikio Namiki, Kazuo Nishimura, Yoshihiko Hirao, Taiji Tsukamoto
Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. Cancer medicine 7 (10) (2018)